MA44381A - Format d'anticorps hétérodimères multispécifiques - Google Patents

Format d'anticorps hétérodimères multispécifiques

Info

Publication number
MA44381A
MA44381A MA044381A MA44381A MA44381A MA 44381 A MA44381 A MA 44381A MA 044381 A MA044381 A MA 044381A MA 44381 A MA44381 A MA 44381A MA 44381 A MA44381 A MA 44381A
Authority
MA
Morocco
Prior art keywords
antibody format
heterodimeric antibody
multispecific heterodimeric
multispecific
format
Prior art date
Application number
MA044381A
Other languages
English (en)
Inventor
Sebastian Meyer
David Urech
Original Assignee
Numab Innovation Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Innovation Ag filed Critical Numab Innovation Ag
Publication of MA44381A publication Critical patent/MA44381A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044381A 2015-06-15 2016-06-15 Format d'anticorps hétérodimères multispécifiques MA44381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001758 2015-06-15

Publications (1)

Publication Number Publication Date
MA44381A true MA44381A (fr) 2019-01-23

Family

ID=53434175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044381A MA44381A (fr) 2015-06-15 2016-06-15 Format d'anticorps hétérodimères multispécifiques

Country Status (13)

Country Link
US (2) US11236150B2 (fr)
EP (2) EP3307776A1 (fr)
JP (3) JP6839101B2 (fr)
KR (2) KR20250091329A (fr)
CN (2) CN107922486B (fr)
AU (3) AU2016278586B2 (fr)
CA (1) CA2989474C (fr)
EA (1) EA201890041A1 (fr)
HK (1) HK1245805A1 (fr)
IL (2) IL293435A (fr)
MA (1) MA44381A (fr)
MX (2) MX395604B (fr)
WO (1) WO2016202457A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX395604B (es) * 2015-06-15 2025-03-25 Numab Therapeutics AG Formato de anticuerpo multiespecífico heterodimérico.
EP3156417A1 (fr) * 2015-10-13 2017-04-19 Affimed GmbH Anticorps fv multivalents
EP3634998B8 (fr) 2017-06-05 2025-04-09 Numab Therapeutics AG Anticorps anti cd3 epsilon
US12098203B2 (en) 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
JP7130678B2 (ja) 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
WO2018224441A1 (fr) 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-cd3
WO2018224439A1 (fr) 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-hsa
EP3459968A1 (fr) 2017-09-20 2019-03-27 Numab Innovation AG Nouvelles combinaisons de structure de domaines variables d'anticorps stables
CN111183159B (zh) 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
JP7791650B2 (ja) 2017-10-10 2025-12-24 ヌマブ セラピューティックス アーゲー Ｐｄｌ１を標的とする抗体及びそれを用いる方法
PE20200849A1 (es) 2017-10-10 2020-08-20 Numab Therapeutics AG Anticuerpo multiespecifico
EP3470426A1 (fr) 2017-10-10 2019-04-17 Numab Therapeutics AG Anticorps multi-spécifique
EP3470428A1 (fr) 2017-10-10 2019-04-17 Numab Innovation AG Anticorps dirigés contre cd137 et leurs procédés d'utilisation
EP3470429A1 (fr) 2017-10-10 2019-04-17 Numab Innovation AG Anticorps dirigés contre pdl1 et leurs procédés d'utilisation
CN111836630A (zh) 2018-01-05 2020-10-27 希望之城 多特异性配体结合物
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (fr) 2018-10-09 2020-04-15 Numab Therapeutics AG Anticorps dirigés contre cd137 et leurs procédés d'utilisation
IL320091A (en) 2019-01-31 2025-06-01 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (fr) 2019-01-31 2020-08-05 Numab Therapeutics AG Anticorps dirigés contre il-17a et leurs procédés d'utilisation
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr) 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
KR20230015957A (ko) * 2020-06-30 2023-01-31 하버 바이오메드 유에스, 아이엔씨. 이중특이적 항체 및 이의 용도
TWI806087B (zh) * 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 免疫細胞銜接多特異性結合蛋白及其製備和應用
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
EP4019546A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps qui se lient à il-31
CA3205037A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps se liant a il-31
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
EP4019090A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps liant il-4r
KR20230166075A (ko) 2021-02-02 2023-12-06 누맙 세러퓨틱스 아게 Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
CN115536749A (zh) 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
EP4183800A1 (fr) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
AU2023265474A1 (en) 2022-05-06 2024-10-31 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb
CN121532211A (zh) 2023-05-19 2026-02-13 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域及抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
JP2006526408A (ja) * 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
WO2010132872A1 (fr) * 2009-05-15 2010-11-18 Novimmune S.A Polythérapies et méthodes utilisant des agents de modulation anti-cd3 et des antagonistes anti-tnf
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US20120195900A1 (en) * 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013003652A1 (fr) * 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Protéines de liaison à domaines variables empilés polyvalentes
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
CN105229034B (zh) * 2013-02-05 2019-12-10 赛诺菲 用于与抗体药物偶联物疗法一起使用的免疫成像剂
KR20160005345A (ko) 2013-05-07 2016-01-14 에프. 호프만-라 로슈 아게 삼량체성 항원 결합 분자
EP2994490A1 (fr) 2013-05-10 2016-03-16 Numab AG Constructions bispécifiques et leur utilisation dans le traitement de plusieurs maladies
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
GB2518221A (en) * 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
EP2930188A1 (fr) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Molécule de liaison à l'antigène trifonctionnel
MX395604B (es) * 2015-06-15 2025-03-25 Numab Therapeutics AG Formato de anticuerpo multiespecífico heterodimérico.
EP3156417A1 (fr) 2015-10-13 2017-04-19 Affimed GmbH Anticorps fv multivalents

Also Published As

Publication number Publication date
CN107922486B (zh) 2022-05-31
EA201890041A1 (ru) 2018-07-31
JP2022177097A (ja) 2022-11-30
US11879005B2 (en) 2024-01-23
IL293435A (en) 2022-07-01
JP2018522545A (ja) 2018-08-16
WO2016202457A8 (fr) 2017-11-30
AU2016278586A1 (en) 2018-01-04
WO2016202457A1 (fr) 2016-12-22
AU2022218544B2 (en) 2025-09-11
AU2022218544A1 (en) 2022-09-15
MX2017016188A (es) 2018-07-06
US20220332797A1 (en) 2022-10-20
EP4047020A1 (fr) 2022-08-24
JP6839101B2 (ja) 2021-03-03
JP7140861B2 (ja) 2022-09-21
NZ738221A (en) 2024-10-25
MX2022011472A (es) 2023-03-01
CN115057936B (zh) 2025-05-30
IL256314B (en) 2022-06-01
KR20250091329A (ko) 2025-06-20
US20180355024A1 (en) 2018-12-13
US11236150B2 (en) 2022-02-01
CA2989474A1 (fr) 2016-12-22
KR20180012860A (ko) 2018-02-06
JP7457764B2 (ja) 2024-03-28
CN107922486A (zh) 2018-04-17
HK1245805A1 (zh) 2018-08-31
JP2021087436A (ja) 2021-06-10
CA2989474C (fr) 2023-09-05
AU2025238141A1 (en) 2025-10-23
MX395604B (es) 2025-03-25
IL256314A (en) 2018-02-28
CN115057936A (zh) 2022-09-16
EP3307776A1 (fr) 2018-04-18
AU2016278586B2 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
EP3359573A4 (fr) Marquage d'anticorps
EP3498840A4 (fr) Anticorps anti-lag-3
MA50352A (fr) Anticorps multispécifiques
EP3423089A4 (fr) Anticorps anti-tigit
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA47268A (fr) Anticorps anti-gpc3
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA47472A (fr) Anticorps
MA44054A (fr) Plateforme d'anticorps bispécifique
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
EP2968553A4 (fr) Formulations d'anticorps
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3349794A4 (fr) Anticorps anti-cd115
MA51134A (fr) Anticorps anti-alpha-synucléine
MA51554A (fr) Anticorps il-6 améliorés